NCT07825688
TxAccess and Dd-cfDNA for Improved Care of Patients With Delayed Graft Function
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Start date pushed from Sep 15, 2026 to Nov 15, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Delayed Graft Function (DGF) severity, defined as time to freedom from dialysis
Timeframe: through 90 days post-transplant
Secondary (6)
Allograft biopsy rate
Health Care Resource Utilization (hospital length of stay)
Health Care Resource Utilization (readmission rate)
Health Care Resource Utilization (days in intensive care unit)
Dialysis utilization
Show 1 moreShow less
Health care related quality of life
Arms and interventions
TxAccess Intervention ArmExperimental
Participants receive standard post-transplant care with deployment of the TxAccess platform and dd-cfDNA monitoring.
Devices: TxAccess
Diagnostic tests: Donor-Derived Cell-Free DNA (dd-cfDNA)